Inclusion Criteria:  Patients will be eligible for inclusion if all the following criteria are respected: male and female (children 3 - 10 years old); acute tonsillitis / rhinopharyngitis (sore throat, catarrhal angina), duration of complaints ≤ 48 hours, Absence of pharyngeal exudate and/or Mc Isaac score 0-1 + negative rapid test for β-hemolytic streptococcus and SARS-CoV-2 identification tonsillitis symptoms score (TSS) ≥ 8 points, both parents capable of and freely willing to provide written informed consent prior to participating in the clinical investigation. for children above 6 years old capable willing to provide written informed consent prior to participating in the clinical investigation.  Exclusion Criteria:  evidence of lacunar or follicular angina. more than two episodes of tonsillitis within the last 12 months, mandatory indication for therapy with antibiotics (e.g., abscess, septic tonsillitis, history of rheumatic fever, post-streptococcus glomerulonephritis, and chorea minor Sydenham), history of close contact with SARS-COV-2 infected individuals in the last 10 days before symptoms onset treatment with antibiotics within 4 months prior to study inclusion, increased hemorrhagic diathesis, chronic diseases (e.g. severe heart, kidney or liver diseases), immunosuppression, known or suspected hypersensitivity to study medication, concomitant treatment potentially influencing study outcome or known interactions with study medication (e.g., coumarin derivatives), participation in another clinical study within the last 3 months prior to clinical investigation inclusion.